SANOFI-AVENTIS (EPA:SAN) FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of =50%
Directive transparence : information réglementée
22/02/2021 19:00
22/02/2021 19:00
09/02/2021 23:15
17/12/2020 22:30
30/11/2020 22:37
30/11/2020 22:15
23/11/2020 22:08
31/07/2020 21:20
31/07/2020 13:00
06/07/2020 22:30
02/07/2020 22:30